News

Gilead Sciences is expected to announce its fiscal second-quarter earnings next month, and analysts forecast a single-digit ...
Rwanda is among the countries interested in Lenacapavir, a newly approved, long-acting preventive injection, though its cost is seemingly out of reach for many developing countries.
DAP Health is presenting “Next Gen Care: A Community Conversation on HIV Prevention,” an event that will highlight ...
Gilead Sciences (GILD) reached $110.17 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.
DAP Health is presenting “Next Gen Care: Innovations in HIV Prevention,” an event that will highlight cutting-edge care and ...
Real Chemistry’s latest acquisition adds up to Greater Than One. | Greater Than One will retain its name and New York City headquarters as it moves under the Real Chemistry umbrella, and its employees ...
Alzheimer's disease, affecting millions, is projected to surge by 2050. Research suggests a potential link between herpes ...
The July 24 event aims to inspire accessible and impactful philanthropy by breaking down barriers to meaningful change.
Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are ...
Several States' Attorneys General reported resolving a case alleging that Gilead Sciences ran an illegal kickback scheme to promote the use of its ...